Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab + TKIs + Chemotherapy in Newly-Diagnosed Ph+ or ABL-Class Ph-Like B-ALL
NCT06124157Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2025
- Primary completion
- Dec 2030
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by National Cancer Institute. Started May 2025; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06124157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06124157.